,會議內(nèi)容,青年論壇開幕式、大會報告分會場（1/2/3）報告分會場（4/5/6）報告,CMV-specific T cell transfer promotes the quantitative and qualitive immune recovery for refractory CMV infection after haploidentical stem cell transplantation（Peking University Peoples Hospital）,Background: Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in allogeneic stem cell transplant (allo-SCT) recipients，particularly in those patients who undergo haploidentical stem cell transplantation (haplo-SCT). Adoptive immunotherapies with CMV-specific T cells have been developed for the treatment of CMV infection，and several clinical trials have established the safety and efficacy of adoptive T cells for prophylaxis and treatment of CMV infection.However，few experiences have been reported about CMV-specific T cells in adoptive therapy post haplo-SCT.,Methods: A total of 32 patients with refractory CMV infection prospectively accepted adoptive CMV-specific T cells infusion following haplo-SCT were enrolled. Another group of 32 patients with non-refractory CMV infection after haplo-SCT was selected as controls. We analyzed the phenotypical and functional characteristics of CMV-specific T cells and their subsets before and after immunotherapy in the refractory CMV cohort， and also in the non-refractory CMV cohort. We aimed to(i) evaluate the safety and antiviral activity of CMV-specific T cells for refractory CMV infection in haplo-SCT recipients.,Results:Of the 32 treated patients，27 cleared CMV within 4 weeks posttransfer and were grouped into the early effective group. The remaining 5 patients who still experienced CMV recurrence after 4 weeks post adoptive transfer were grouped into the late effective group. In the early effective group，in vivo expansion of CMV-specific T cells，as well as improved cytokine production and proliferation ability of CMV-specific T cells were observed following cellular therapy. However，in remaining 5 patients who had CMV recurrence after 4 weeks post-transfer，neither the quantity nor the function of CMV-specific T cells were reversed.,Conclusions: Adoptive transfer of CMV-specific T cells would promote the quantitative and functional recovery of CMVspecific T cells that would guard against refractory CMV infection after haplo-SCT.,18 casesIn 83% of cases CMV infection was cleared or viral burden was significantly reduced Viral control was associated with in vivo expansion of CMV-specific T cells,異體干細胞治療牙周炎的基礎(chǔ)及轉(zhuǎn)化臨床研究王松靈首都醫(yī)科大學(xué),在大型動物模型-小型豬上建立了牙周炎模型。用自體、異體牙源干細胞成功修復(fù)牙周炎致牙周骨缺損。牙源性干細胞再生牙周的效果比非牙源性干細胞好；牙髓干細胞保持細胞的干性及抗凋亡衰老能力明顯優(yōu)于其他干細胞。牙髓干細胞懸液注射組可以用于相對輕型的牙周病組織再生。18例異體牙髓干細胞治療慢性牙周炎臨床研究表明有明顯牙周組織再生，無副作用。通過建立牙源干細胞庫、牙髓干細胞注射液新藥應(yīng)用到臨床,人牙髓間充質(zhì)干細胞注射液,自體干細胞技術(shù)的臨床應(yīng)用肖海蓉石桂來博雅干細胞科技有限公司,博雅集團旗下 Cesca 公司(納斯達克上市企業(yè))是全球領(lǐng)先的干細胞自動化設(shè)備供應(yīng)商，擁有全球市場占有率超過 60%的臍帶血干細胞自動化分離設(shè)備(AutoXpress)及全球唯一的自動化液氮存儲裝置(BioArchive)。利用自主研發(fā)的手術(shù)室即時系統(tǒng)(ResQTM60、 MarrowXpressTM)，Cesca公司開展了自體骨髓單核細胞治療重癥下肢缺血、急性心肌梗死、骨折不愈合等疾病的臨床研究。其中，重癥下肢缺血的 1/II 期臨床試驗(n=17)已經(jīng)完成， 患者無治療相關(guān)副作用，1年無截肢生存率為 82.4%，旁側(cè)血管數(shù)量與尺寸等指標顯著改善； FDA 已經(jīng)批準開展 III 期臨床試驗。,臨床級臍帶間充質(zhì)細胞制備及鑒定方法研究袁艷鵬等首都醫(yī)科大學(xué)宣武醫(yī)院,目的：在 GLP 實驗室中制備并鑒定臨床級臍帶間充質(zhì)細胞方法：新鮮獲取的臍帶去除血管并進行充分清洗，獲得的華通膠(Whartons jelly)機械分離后分別進行直接貼壁法和不同的酶消化法，比較獲取臍帶間充質(zhì)細胞的數(shù)量差別；用不同的無血清培養(yǎng)基進行培養(yǎng)比較細胞形態(tài)是否良好， 得到最佳形態(tài)的臍帶間充質(zhì)細胞。體外培養(yǎng)第 3 代后進行臍帶間充質(zhì)細胞質(zhì)檢，包括細胞活性，生長曲線，無菌檢測，人類相關(guān)病毒、支原體、內(nèi)毒素檢測，染色體核型分析， FACS 免疫表型檢測及分化能力檢測。 不同消化方法獲取細胞數(shù)之間比較采用兩樣本配對 t 檢驗。,結(jié)果:膠原酶消化獲得的臍帶間充質(zhì)細胞數(shù)(5.3106/ml)與膠原酶+0.25胰酶消化法(2.53105/ml)及直接貼壁法(2.6105/ml)之間存在顯著性差異(P0.0001)；MesenCult-ACF Medium （上海鈺博生物）培養(yǎng)獲得的 UC-MSC 形態(tài)最佳； UC-MSC 質(zhì)檢細胞活性凍存前達99.8， 凍存復(fù)蘇后達 99； 無細菌/支原體/乙肝病毒/丙肝病毒/梅毒螺旋體/艾滋病毒/肺炎支原體/EB 病毒/巨細胞病毒污染； 內(nèi)毒素檢測結(jié)果均1EU； CD73/CD90/CD105 陽性率達98， CD